B-lymphoblastic leukaemia presenting as intrahepatic cholestasis
Daniyal Raza*1, Maryam Mubashir*2, Karan Sachdeva1, Lena Kawji1, Ashley Deville1, Syed Musa Raza2, James Morris2, Sudha Pandit2
1 Department of Internal Medicine, LSU Health Shreveport, Shreveport, United States
2 Department of Gastroenterology and Hepatology, LSU Health Shreveport, Shreveport, United States
* Contributed equally
Doi: 10.12890/2023_004121 - European Journal of Case Reports in Internal Medicine - © EFIM 2023
Received: 21/09/2023
Accepted: 11/10/2023
Published: 30/10/2023

How to cite this article: Raza D, Mubashir M, Sachdeva K, Kawji L, Deville A, Raza SM, Morris J, Pandit S. B-lymphoblastic leukaemia presenting as intrahepatic cholestasis. EJCRIM 2023;10:doi:10.12890/2023_004121.

Conflicts of Interests: The authors declare there are no competing interests.
Patient Consent: We have obtained written consent from the patient.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License


Acute cholangitis is a critical medical condition requiring prompt intervention. This case report explores the complexities and uncertainties encountered in clinical decision-making when faced with a patient presenting with symptoms suggestive of acute cholangitis. We emphasise the importance of considering individual circumstances and factors in the diagnostic process. A 38-year-old woman with a history of Crohn’s colitis presented with abdominal pain, jaundice and leukocytosis. Initial evaluation raised suspicions of acute cholangitis, but unexpected findings of blast cells in the peripheral smear led to a diagnosis of B-lymphoblastic leukaemia with BCR-ABL1 fusion. Treatment with steroids and chemotherapy resulted in the resolution of liver abnormalities. This case underscores the necessity of comprehensive assessments for obstructive jaundice and highlights the potential diagnostic challenges posed by underlying haematologic malignancies. It also raises awareness about drug-induced liver injury, and emphasises the importance of complete blood counts and differentials in the initial workup. Healthcare providers should be vigilant in considering alternative diagnoses when faced with obstructive jaundice, as misdiagnosis can lead to invasive procedures with potential adverse events.



ERCP, B-ALL, intrahepatic cholestasis


Acute cholangitis is a potentially life-threatening condition that requires immediate treatment to prevent fatal outcomes. It is estimated that there are fewer than 20,000 reported cases of acute cholangitis in the United States each year, with the majority of cases occurring in individuals aged 50 to 60[1]. As the Tokyo Guidelines outline, urgent biliary decompression is strongly recommended when a patient presents with Charcot’s triad and meets the criteria for moderate to severe cholangitis[2]. Following the Tokyo Guidelines helps minimise false positive results and improves diagnostic accuracy[3]. However, there are situations where clinical decision-making becomes complex and is not straightforward. Our case study explores the challenges and hesitations encountered when making treatment decisions due to various confounding factors. This case underscores the importance of considering individual circumstances and factors in decision-making.


A 38-year-old woman with a history of Crohn’s colitis and on adalimumab presented with progressively worsening upper abdominal pain, nausea, vomiting, decreased appetite, a change in urine colour and chills. The patient had recently completed a course of amoxicillin and clavulanic acid for an upper respiratory tract infection, and was recovering from an alcohol use disorder. On presentation, she was afebrile and haemodynamically stable. On examination, she had bilateral scleral icterus and was not in acute distress. The abdomen was distended, soft, and tender to palpation. Splenomegaly and hepatomegaly were also detected, with the liver measuring 5 cm below the costal margin.
Laboratory results revealed lymphocytic leukocytosis (16 K/ul), thrombocytopenia (59 K/ul), and elevated liver function tests (alkaline phosphatase 316 U/l, total and direct bilirubin 7/6.3 mg/dl, AST/ALT 72/131 U/l) (Fig. 1). Despite the history of alcohol consumption, elevation in transaminases did not fit the clinical picture of acute alcoholic hepatitis. To further evaluate her condition, a computed tomography (CT) abdomen pelvis scan and ultrasound of the liver with doppler were performed, which showed normal common bile ducts, intra- and extrahepatic biliary ducts, and moderate hepatosplenomegaly (Fig. 2).

(click to enlarge)

Figure 1. Liver biopsy showing leukaemia cells invading the liver

(click to enlarge)

Figure 2. Hepatosplenomegaly showed no intra- or extrahepatic biliary dilation

Due to the patient presenting with symptoms of abdominal pain, jaundice and leukocytosis, the gastroenterology team was consulted to assess the potential presence of cholangitis and to decide on the necessity of endoscopic retrograde cholangio pancreatography (ERCP). However, the initial evaluation took an unforeseen turn when a peripheral smear was ordered to investigate acute thrombocytopenia and unexpectedly revealed blast cells, drastically altering the clinical outlook. Subsequent investigations, including flow cytometry and bone marrow biopsy, confirmed a diagnosis of B-lymphoblastic leukaemia with BCR-ABL1 fusion, accounting for 97% of cellularity on the differential count.
Due to the initial high liver function test results, the patient required the initiation of steroids, followed by treatment with rituximab and Hyper-CVAD (cyclophosphamide, vincristine, adriamycin and dexamethasone) with the dose adjusted based on liver function/T bilirubin levels. Additionally, the patient commenced dasatinib due to a positive Philadelphia chromosome, while rituximab was administered for the CD20+ status. Following this treatment, the patient’s liver enzymes returned to normal levels.


B-cell lymphocytic leukaemia is a haematologic cancer that arises in the bone marrow and has the potential to spread to other organs through metastasis. Our case underscores the significance of carefully determining the underlying cause of obstructive jaundice in individuals with acute leukaemia, while maintaining a comprehensive approach during the initial assessment. We also considered the potential of drug-induced liver injury from amoxicillin and clavulanic acid, as the patient had recently used this medication for a respiratory tract infection and there were concerns about mixed cholestatic-hepatocellular injury, as previously reported[16]. The case also strongly emphasises the critical role of conducting a complete blood count and differential as part of the initial workup for any patient displaying symptoms suggestive of liver involvement.
Importantly, it should be noted that the patient was also receiving adalimumab, a medication that the Food and Drug Administration (FDA) has associated with a potential risk of inducing lymphoma and malignancies, especially in children and adolescents. Intrahepatic cholestasis in haematologic malignancies is not infrequent, though it is rarely the initial presentation. B-cell acute lymphoblastic leukaemia (B-cell ALL)[6,9] and T-cell acute lymphoblastic leukaemia (T-cell ALL)[10] rarely exhibit symptoms of jaundice, making the initial presentation with obstructive jaundice a rarity. While a few cases have been observed in the paediatric population, even fewer have been reported in adults[11]. Very few cases of cholestatic hepatitis due to diffuse sinusoidal infiltration of the liver have also been reported in acute myeloid leukaemia, which also happened in our case[17].
Based on an analysis of liver specimens from an autopsy series published in 1995, it was discovered that in untreated patients with leukaemia and lymphomas, neoplastic involvement was observed in 44% of cases. Additionally, among patients who underwent chemotherapy, either as a standalone treatment or in conjunction with radiotherapy, 26% exhibited comparable indications of neoplastic presence in the liver[5]. Malignant biliary obstruction predominantly stems from cholangiocarcinoma and pancreatic adenocarcinoma[15]. Other contributing factors include hepatocellular carcinoma, gallbladder carcinoma and lymphoma as in our patient.
Haematologic malignancies can manifest with varying patterns of hepatic involvement. Some patients may remain asymptomatic, with hepatic lesions being incidentally discovered. However, certain individuals may present alarming signs and symptoms of acute hepatic failure[4,7,13,]. The pathophysiology of obstructive jaundice in patients with acute lymphoblastic leukaemia (ALL) can vary. It can encompass a spectrum of mechanisms, ranging from the obstruction of the biliary duct, as observed in a case of acute myeloid leukaemia[8], formation of a bile duct stricture in a case of B-ALL[18], to the infiltration of hepatic sinusoids by tumour cells, as seen in the present case. According to certain authors[8], prednisone can be considered before initiating chemotherapy as a treatment approach. Once bilirubin levels have started to decrease, chemotherapy can be administered[12]; our patient followed a similar treatment course in this regard. Haematologic malignancies should always be considered as a possible cause in patients presenting with constitutional symptoms and hepatosplenomegaly. While a liver biopsy and immunohistochemical stains can confirm the diagnosis by revealing immature B-cell lineage, it is not always necessary, as demonstrated in the aforementioned case. Systemic chemotherapy is the primary treatment modality for B-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma (B-ALL/LBL).


Leukaemic infiltration of liver causing intrahepatic cholestasis as in our patient can be a diagnostic dilemma. Establishing the correct diagnosis has important implications since the treatment of choice for the alternate diagnosis – ERCP – is not only invasive but also has high risk of adverse events[14]. By carefully discerning the cause of obstructive jaundice, healthcare providers can make informed decisions regarding treatment options and optimise patient care.

  1. Ahmed M. Acute cholangitis – an update. World J Gastrointest Pathophysiol 2018;9:1–7.
  2. Zimmer V, Lammert F. Acute bacterial cholangitis. Viszeralmedizin 2015;31:166–172.
  3. Hudgi A, Cartelle AL, Ahmed A, Alkaddour A, Palacio C, Vega KJ, et al. Tokyo Guidelines (TG18) for acute cholangitis provide improved specificity and accuracy compared to fellow assessment. Cureus 2022;14:e27527.
  4. Devictor D, Tahiri C, Fabre M, Mielot F, Dussaix, E. Early pre-B acute lymphoblastic leukemia presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr 1996;22:103–106.
  5. Scheimberg IB, Pollock DJ, Collins PW, Doran HM, Newland AC, van der Walt JD. Pathology of the liver in leukaemia and lymphoma. A study of 110 autopsies. Histopathology 1995;26:311–321.
  6. Goor Y, Goor O, Michalewitcz R, Cabili S. Acute myeloid leukemia presenting as obstructive jaundice. J Clin Gastroenterol 2002;34:485-486.
  7. Zafrani ES, Leclercq B, Vernant JP, Pinaudeau Y, Chomette G, Dhumeaux D. Massive blastic infiltration of the liver: a cause of fulminant hepatic failure. Hepatology 1983;3:428–432.
  8. Rajesh G, Sadasivan S, Hiran KR, Nandakumar R, Balakrishnan V. Acute myeloid leukemia presenting as obstructive jaundice. Indian J Gastroenterol 2006;25:93–94.
  9. Daniel SV, Vani DH, Smith AM, Hill QA, Menon KV. Obstructive jaundice due to a pancreatic mass: a rare presentation of acute lymphoblastic leukaemia in an adult. JOP 2010;11:72-74.
  10. Patel KJ, Latif SU, de Calaca WM. An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report. J Hematol Oncol 2009;2:12.
  11. Kelleher JF, Monteleone PM, Steele DA, Gang DL, Angelides AG. Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2001;23:117–121.
  12. Comeau TB, Phillips DL. Chemotherapy dosing with elevated liver function test results in acute leukemia. Ann Pharmacother 2005;39:1752–1754.
  13. Felice MS, Hammermuller E, De Dávila MT, Ciocca ME, Fraquelli LE, Lorusso AM, et al. Acute lymphoblastic leukemia presenting as acute hepatic failure in childhood. Leuk Lymphoma 2000;38:633–637.
  14. ASGE Standards of Practice Committee; Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, et al. Adverse events associated with ERCP. Gastrointest Endosc 2017;85:32–47.
  15. Leng J-J, Zhang N, Dong J-H. Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction: a meta-analysis. World J Surg Oncol 2014;12:272.
  16. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015;148:1340–1352.
  17. Wandroo FA, Murray J, Mutimer D, Hubscher S. Acute myeloid leukaemia presenting as cholestatic hepatitis. J Clin Pathol 2004;57:544–545.
  18. Melendez-Rosado J, Bartel MJ, Jiang L, Lukens F. B cell acute lymphocytic leukemia presenting as a bile duct stricture diagnosed with cholangioscopy. ACG Case Rep J 2016;3:e107.